WallStSmart

Alcon AG (ALC)vsLeMaitre Vascular Inc (LMAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 4039% more annual revenue ($10.86B vs $262.43M). LMAT leads profitability with a 25.0% profit margin vs 5.9%. ALC appears more attractively valued with a PEG of 1.27. LMAT earns a higher WallStSmart Score of 62/100 (C+).

ALC

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

LMAT

Buy

62

out of 100

Grade: C+

Growth: 7.3Profit: 8.5Value: 4.0Quality: 8.5
Piotroski: 4/9Altman Z: 3.16
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-22.0%)

Margin of Safety

-22.0%

Fair Value

$65.08

Current Price

$66.03

$0.95 premium

UndervaluedFair: $65.08Overvalued
LMATSignificantly Overvalued (-55.5%)

Margin of Safety

-55.5%

Fair Value

$56.44

Current Price

$80.59

$24.15 premium

UndervaluedFair: $56.44Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

LMAT4 strengths · Avg: 8.8/10
Altman Z-ScoreHealth
3.1610/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
25.0%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
29.0%8/10

Strong operational efficiency at 29.0%

EPS GrowthGrowth
22.6%8/10

Earnings expanding 22.6% YoY

Areas to Watch

ALC4 concerns · Avg: 2.8/10
Return on EquityProfitability
3.8%3/10

ROE of 3.8% — below average capital efficiency

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
53.8x2/10

Premium valuation, high expectations priced in

LMAT3 concerns · Avg: 3.7/10
PEG RatioValuation
2.114/10

Expensive relative to growth rate

P/E RatioValuation
27.8x4/10

Moderate valuation

Market CapQuality
$1.82B3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Price/Book, Debt/Equity. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bull Case : LMAT

The strongest argument for LMAT centers on Altman Z-Score, Profit Margin, Operating Margin. Profitability is solid with margins at 25.0% and operating margin at 29.0%.

Bear Case : ALC

The primary concerns for ALC are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 53.8x leaves little room for execution misses.

Bear Case : LMAT

The primary concerns for LMAT are PEG Ratio, P/E Ratio, Market Cap.

Key Dynamics to Monitor

ALC profiles as a value stock while LMAT is a mature play — different risk/reward profiles.

ALC carries more volatility with a beta of 0.70 — expect wider price swings.

LMAT is growing revenue faster at 9.6% — sustainability is the question.

ALC generates stronger free cash flow (414M), providing more financial flexibility.

Bottom Line

LMAT scores higher overall (62/100 vs 51/100), backed by strong 25.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

LeMaitre Vascular Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.

Want to dig deeper into these stocks?